Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of AD-221 vs Co-administered AD-221A and AD-221B in Healthy Males
NCT05202405Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin and ezetimibe in hyperlipidemia (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Started Jan 2022; status: completed.
02
Drugs
atorvastatinezetimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05202405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202405.